Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Study save search
Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
Published: 2023-12-07 (Crawled : 21:00) - globenewswire.com
RMD | $163.49 -0.31% 0.0% 820K
|
Health Technology
| Email alert
Add to watchlist
RSMDF S | $ 0%
|
Health Technology
| Email alert
Add to watchlist
copd study
Alabama Power ranked #1 among large utilities in the South in 2023 J.D. Power Electric Utility Business Customer Satisfaction Study
Published: 2023-12-07 (Crawled : 18:00) - prnewswire.com
SO | $71.65 -0.84% 0.0% 3.6M
|
Utilities
| Email alert
Add to watchlist
business study
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Published: 2023-12-07 (Crawled : 14:30) - globenewswire.com
BMEA A | $15.02 -18.59% -22.84% 3.8M
|
Professional, Scientific, and T...
|
| O: -0.85%
H: 0.0%
C: 0.0%
alent-111 disease congress world ongoing bmf-219 diabetes cardiovascular results insulin study
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
Published: 2023-12-07 (Crawled : 13:30) - globenewswire.com
ABVC | $1.24 -8.15% -8.87% 430K
|
Wholesale Trade
|
| O: -4.81%
H: 0.0%
C: 0.0%
treatment biopharma adhd study
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
Published: 2023-12-07 (Crawled : 13:00) - globenewswire.com
MBOT | $1.225 1.24% 1.22% 210K
|
Health Technology
|
| O: 3.28%
H: 0.0%
C: 0.0%
pre-clinical medical milestone study submission
HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1
Published: 2023-12-07 (Crawled : 13:00) - prnewswire.com
HRMY | $31.07 -3.09% -3.19% 780K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
positive topline study
Lightbridge and Centrus Energy Enter into a Contract to Conduct a FEED Study for a Lightbridge Pilot Fuel Fabrication Facility in Piketon, Ohio
Published: 2023-12-07 (Crawled : 12:00) - globenewswire.com
LTBR | News A | $3.745 11.79% 10.55% 260K
|
Commercial Services
|
| O: 8.36%
H: 0.0%
C: 0.0%
LEU | $49.7 -3.27% 0.0% 150K
|
Non-Energy Minerals
|
| O: -1.38%
H: 0.0%
C: 0.0%
energy contract pilot study
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
Published: 2023-12-07 (Crawled : 01:00) - prnewswire.com
SNY | News | $46.06 0.17% 0.17% 1.9M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
positive ongoing collaboration study
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 23:00) - prnewswire.com
ANIX | News | $3.6 -8.4% -9.17% 1.1M
|
Health Technology
| Email alert
Add to watchlist
vaccine breast positive cancer study
Metastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsight
Published: 2023-12-06 (Crawled : 22:00) - prnewswire.com
LLY | News 5 d | $588.27 -0.17% -0.1% 2.1M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
cancer study market
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 21:00) - prnewswire.com
ANIX | News | $3.6 -8.4% -9.17% 1.1M
|
Health Technology
| Email alert
Add to watchlist
conference vaccine breast positive cancer ongoing study
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
Published: 2023-12-06 (Crawled : 21:00) - globenewswire.com
CMPS | News | $5.97 7.76% 7.2% 410K
|
Health Technology
|
| O: 1.34%
H: 0.0%
C: 0.0%
depression treatment psilocybin results study
SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS
Published: 2023-12-06 (Crawled : 17:00) - biospace.com/
SERA | News | $5.02 -8.56% -9.36% 3.8M
|
|
| O: 141.19%
H: 0.0%
C: 0.0%
success prime study
75% of the Industrial Sector Experienced a Ransomware Attack in the Past Year, Claroty Study Finds
Published: 2023-12-06 (Crawled : 14:30) - prnewswire.com
ROK | News A | $277.89 -0.08% 0.0% 490K
|
Producer Manufacturing
|
| O: 0.57%
H: 0.0%
C: 0.0%
study
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
JAGX | News | $0.2863 -10.53% -11.77% 4.2M
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
breast health life symposium cancer pharmaceuticals family study
CENTURY LITHIUM PROVIDES UPDATE ON FEASIBILITY STUDY AND SODIUM HYDROXIDE AS A BY-PRODUCT
Published: 2023-12-06 (Crawled : 13:30) - prnewswire.com
CYDVF | News | $0.4 7.5% 260K
|
Non-Energy Minerals
| Email alert
Add to watchlist
LTUM | News | $0.048 6.25% 58K
|
Mining, Quarrying, and Oil and ...
| Email alert
Add to watchlist
lithium update study
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
Published: 2023-12-06 (Crawled : 13:00) - globenewswire.com
COCP | News | $1.77 5.05% 4.8% 11K
|
Health Technology
| Email alert
Add to watchlist
cc-4234 pharma influenza study cc-42344
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
Published: 2023-12-06 (Crawled : 12:30) - globenewswire.com
IPSC | News | $2.29 6.51% 6.11% 250K
|
Professional, Scientific, and T...
|
| O: 3.01%
H: 0.0%
C: 0.0%
cnty-101 conference lupus lymphomas trial therapeutics study
BullFrog AI Launches Preclinical Study to Investigate BF-114’s Potential in Battling Obesity
Published: 2023-12-06 (Crawled : 12:00) - globenewswire.com
BFRG | News | $2.45 -5.41% -5.71% 76K
|
n/a
|
| O: 3.38%
H: 0.0%
C: 0.0%
bf-114 obesity preclinical potential study
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
Published: 2023-12-06 (Crawled : 12:00) - globenewswire.com
PHVS | News 0 d | $25.57 3.31% 3.21% 510K
|
|
| O: 31.9%
H: 0.0%
C: 0.0%
positive treatment study
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
SLDB M | $5.89 72.22% 41.94% 12M
|
Health Technology
SVFD | $3.09 43.72% 30.42% 64M
|
FTEL | $2.04 43.66% 30.39% 110K
|
HPCO 4 | $0.4824 41.92% 29.54% 28M
|
ALGS | $0.6475 -5.06% 26.67% 2.1M
|
Health Technology
GTHX | $3.16 30.58% 23.42% 10M
|
Health Technology
KEQU | News | $22.5 27.62% 21.64% 24K
|
Producer Manufacturing
GSIT | $3.09 27.16% 21.36% 2.2M
|
Electronic Technology
SSKN P | $0.628 25.6% 20.38% 210K
|
Health Technology
GLUE | $3.66 22.82% 18.58% 510K
|
Professional, Scientific, and T...
Your saved searches
Save your searches and get alerts when important news are released.